vYF + MMR II

vYF + MMR II refers to the co-administration of Sanofi's investigational live-attenuated yellow fever vaccine (vYF, also known as SP0218) and Merck's licensed M-M-R II vaccine. This combination is being evaluated in Phase III clinical trials for pediatric populations, specifically infants aged 11-15 months, to assess the safety and immunogenicity of giving both vaccines during the same vaccination visit. vYF is designed to provide immunity against the yellow fever virus, while M-M-R II is a trivalent vaccine providing protection against measles, mumps, and rubella infections. The study aims to demonstrate that the immune response to each component is not compromised when administered concomitantly.

Other names

vYF + M-M-R IISP0218 + MMR IIyellow fever vaccine + measles, mumps, and rubella vaccine